Merck, a global leading science and technology health care company, has relaunched its type 2 diabetes drugs, Glucovance and Glucophage in Lagos, Nigeria.
The event, which held at Shoregate Hotels, GRA, Ikeja, and chaired by Prof. Adesoji Fasanmade, head, department of medicine (Endocrinology Unit), University College Hospital, Ibadan, was also graced by other distinguished physicians amongst whom were Dr Henry Onyegbutulem, consultant physician, Asokoro General Hospital, Abuja; Dr Ifeday Odeniyi, senior lecturer, College of Medicine, University of Lagos; and Dr Harry Kowlet, a diabetes specialist/independent consultant, University of St. Andrews, United Kingdom (UK).
Speaking at the occasion, Pharm. Charles Ajibo, general manager, Merck Nigeria, said that the relaunch of the drugs was to re-emphasise the fact that Glucophage and Glucovance, which had hitherto been distributed in Nigeria by designated agents, were now being distributed by the company (Merck), following its return to the country in 2014.
“Prior to 2014, Merck was represented in Nigeria by agents; so all products of Merck in Nigeria were distributed by agents. But we are now present in Nigeria as Merck and we are relaunching our brands in order to re-establish the priorities to our country that these good, trusted and verifiable products are still here in Nigeria and being distributed by Merck,” Pharm. Ajibo said.
While also speaking at the occasion, Dr Henry Onyegbutulem commended Merck for relaunching the diabetes drugs, disclosing that he had used Glucovance to treat patients and had found it very useful in the treatment of type 2 diabetes.
Dr Ifedayo Odeniyi in his remarks opined that the Nigerian government should start subsidising healthcare delivery and should also enhance the operation of the National Health Insurance Scheme (NHIS).
Professor Fasanmade, the chairman of the occasion, stated that 90 per cent of diabetes patients in Nigeria have type 2 diabetes. He said studies have shown Glucovance is effective in managing the condition.